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Th2-cytokinesAlthough numerous studies demonstrate the participation of nitric oxide (NO) in various inﬂammatory diseases,
the precise function of NO in allergic asthma remains unclear. We investigated whether iNOS inhibition could
interfere with the kinetics of VLA-4 andMac-1 expression and adhesion properties of bone marrow and peripheral
blood eosinophils of sensitized mice after antigen exposure. Treatment of allergic mice with 1400W (iNOS
inhibitor) increased the adhesion of bone marrow eosinophils to ICAM-1, but not blood eosinophils, at 24 h and
48 h after OVA-challenge. Conversely, adhesion of blood eosinophils from 1400W-treated mice to VCAM-1
diminished at 24 h and was almost completely blocked at 48 h. 1400W did not induce any change in the adhesion
of bone marrow eosinophils to VCAM-1, at 24 h, but cells collected 48 h after challenge showed signiﬁcantly lower
adherence. Flow cytometry demonstrated that 1400W resulted in a signiﬁcantly increased Mac-1 expression on
bone marrow eosinophils at 24 h, as compared to control mice. However, at 24 h, 1400W signiﬁcantly decreased
Mac-1 and VLA-4 expressions on blood eosinophils. At 48 h, the expressions of both Mac-1 and VLA-4 returned to
previous levels. Results show a temporal effect of iNOS upon Mac-1 expression and function, the chief adhesion
molecule involved in the eosinophil efﬂux from the bone marrow at 24 h. In contrast, Mac-1 and VLA-4 were
involved in eosinophil mobilization from blood to lungs at 48 h after antigen challenge. Data suggest an important
role of the Mac-1 and VLA-4 in the iNOS-modulated migration of eosinophils to the lungs of allergic mice.nducible nitric oxide synthase;
function-associatedmolecule-1;
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Asthma is a chronic inﬂammatory disease of the respiratory tract,
characterized by an accumulation of eosinophils, mast cells, and
activated lymphocytes in lung tissues [1]. In allergic diseases, it has
been suggested that T helper (Th) cells, through the release of speciﬁc
cytokines, orchestrate the inﬂammatory response leading to pulmonary
eosinophil accumulation. It is now recognized that allergic asthma is
driven by a Th1/Th2-cytokine imbalance that favors Th2 activation [2].
Th2 cytokines, such as IL-4 and IL-13, promote immunoglobulin isotype
class switching to IgE and are also involved in mucus hypersecretion andallergen-induced airway hyper-responsiveness [2]. Additionally, IL-5 is
involved in the maturation of eosinophils and basophils, the main
effector cells that secrete mediators of the allergic response [1].
Regulatory T cells have been implicated in the suppression of Th2-cell
responses involving the inhibitory cytokines, IL-10 and TGFβ [3]. There is
strong evidence that the CC chemokines, eotaxin and RANTES, act in
synergy with Th2 cytokines to recruit eosinophils to asthmatic airways
[4]. Among the cytokines implicated in leukocyte recruitment, only IL-5
and eotaxin selectively regulate eosinophil trafﬁcking [5].
Inﬂammatory diseases of the airways are commonly associated
with elevated production of nitric oxide (NO) and increased indices of
NO-dependent oxidative stress. Asthma is often characterized by an
increased expression of the inducible isoform of nitric oxide synthase
(iNOS) within respiratory epithelial and inﬂammatory immune cells,
and a markedly elevated local production of NO [6]. Recent data
indicate that the measurement of exhaled nitric oxide in exhaled air
may be a useful biomarker of asthma [7].
Several studies have revealed that the NO produced during the
allergic inﬂammatory responses is involved in the up-regulation of
eosinophil migration to airways [8–13], although the mechanism by
which NO promotes allergic eosinophil inﬂux in allergic inﬂammation
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regulate cytokine production and adhesion molecule expression and
function, where the VLA-4 (CD49d/CD29) and Mac-1 (CD11b/CD18)
integrins are thought to be key adhesion molecules involved in
eosinophil accumulation in several allergic disorders. In turn, VCAM-1
and ICAM-1, expressed on endothelial cells, act as receptors for VLA-4
and Mac-1, respectively. [14].
Our previous study suggests that inhibition of NO synthesis could
delay efﬂux of eosinophils from bone marrow to peripheral blood that
could result in reduced eosinophil inﬁltration to the lungs [13], however
the NOS isoform involved in this mechanism remains undeﬁned. While
some studies using iNOS-deﬁcient animals or iNOS inhibitors, such as the
highly selective iNOS inhibitor 1400W, indicate participation of iNOS in
eosinophil migration [11,15,16], others have not found any association
between the iNOS isoform and eosinophil recruitment to the lungs
[8,12,17]. The purpose of this study was to investigate whether iNOS
inhibition could interfere with the kinetics of VLA-4 and Mac-1
expression on the eosinophils of the bone marrow and peripheral
blood after antigen exposure. Additionally, we evaluated the adhesion of
eosinophils to immobilized VCAM-1 and ICAM-1 and the levels of the
C-C chemokine, eotaxin, and cytokines secreted by Th2 lymphocytes
(IL-4, IL-5 and IL-13) in lung tissue.2. Material and methods
2.1. Drugs
The following materials and reagents were used: Ovalbumin (OVA
grade V), Eagle's minimum essential medium (MEM) and Protease
Inhibitor Cocktail (Sigma Chem. Co., St. Louis, MO, USA); N-3-
aminomethyl-benzyl-acetamidine-dihydrochloride (1400W; Calbio-
chem, San Diego, CA); neutralizing antibodies to VLA-4 and Mac-1,
PE-conjugated anti-CD49d and PeCy7-conjugated anti-CD11a (BD
Bioscience, San Jose, CA, USA); recombinant mouse VCAM-1 and
ICAM-1, IL-4, IL-5, IL-13, eotaxin immunoassay kit and FITC-conjugated
anti-CCR3 (R&D System, Minneapolis, USA); APC-conjugated anti-
CD11b (eBioscience, San Diego, CA, USA).2.2. Animals
This study was approved by the Animal Ethics Committee of San
Francisco University, Brazil. Female BALB/c mice, 5–8 weeks old, were
obtained from the Multiinstitutional Centre for Biological Investigation
(CEMIB), State University of Campinas (UNICAMP), Brazil. Themice were
maintained under conventional animal housing conditions with food
and water ad libitum.2.3. Sensitization, airway challenge and treatment
Mice were sensitized subcutaneously at day 0 and day 7 with 400 μl
of a suspension of 100 mg ovalbumin (OVA grade V) bound to 4 mg of
aluminum hydroxide, prepared in PBS. Seven days after the second
sensitization, the animals were brieﬂy anesthetized with halothane and
challenged intranasally with either 10 μg of OVA in 50 μl of sterile saline
or with saline alone. These OVA or saline exposures were performed
twice a day for 4 consecutive days. Groups of animals were treated with
the iNOS-speciﬁc inhibitor, N-3-aminomethyl-benzyl-acetamidine-dihy-
drochloride (1400W; 1.0 mg/kg in 300 μl of sterile saline). The inhibitor
was administered intraperitoneally (i.p.) at 2 h before and 4 h and 12 h
after OVA-challenge. Control groups received saline i.p. alone. Thus, for
each time-point after challenge, our protocols resulted in four
experimental groups: (1) control non-challenged; (2) control OVA-
challenged; (3) 1400W non-challenged; (4) 1400W OVA-challenged. All
groups were sensitized with OVA.2.4. Cell collection and sample processing
To obtain the bronchoalveolar lavage (BAL), mice were anesthetized
with halothane, peripheral blood was collected, and lungs were washed
four times with 500 μl of saline. The samples were immediately
centrifuged (20 °C, 300×g, 10 min); the pellet was resuspended in
Eagle's minimum essential medium (MEM; pH 7.2) and the supernatant
was collected and frozen at−80 °C. After the BAL procedure, lungs were
removed from the mice, ﬂash frozen in liquid nitrogen and stored at
−80 °C. Femurs were isolated from the mice to obtain the bone marrow.
The epiphyses were cut transversely and bone marrow cells were
ﬂushed out with PBS containing heparin (20 UI/ml). The red blood cells
of peripheral blood and bone marrow were then lysed with lysis buffer
(155 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA) for 15min at 4 °C. The
white blood cells were resuspended in Eagle's minimum essential
medium (MEM), pH 7.2, with 0.01% bovine serum albumin. The total cell
numbers in bone marrow, blood and BAL were determined using
standard hematological procedures. Differential leukocyte counts were
carried out on a minimum of 400 cells using cytospin preparation of the
cell suspension, stained with Diff-Quick (Scientiﬁc Products). Both bone
marrow and blood eosinophils were evaluated as a mixture of mature
and immature forms, as recognized by the intensely eosinophilic
granules. For bone marrow and BAL cell analysis, as well as cytokine
measurements, the mice were killed at 24 h, 48 h, 72 h and 96 h after the
ﬁrst challenge. In vitro eosinophil adhesions and ﬂow cytometric
analyses were carried out at 24 h and 48 h after the ﬁrst challenge.
2.5. Eosinophil cell adhesion assays
The assay was carried out employing a previously described
method. In brief, bone marrow and peripheral blood cells (1.0×106
cells/ml) were pre-incubated with or without neutralizing antibodies
to VLA-4 and Mac-1 (10 μg/ml) for 20 min at 4 °C. Subsequently, the
cells were subjected to an adhesion assay in 96-well plates pre-coated
with recombinant mouse VCAM-1 (2.5 μg/ml) or with recombinant
mouse ICAM-1 (5.0 μg/ml) for 15 min at 37 °C, 5% CO2. After
incubation, non-adhered cells were removed and the remaining
cells were washed twice with PBS. Fifty microliters of varying
concentrations of the original cell suspension in minimum essential
media (MEM) were added to empty wells to form a standard curve.
Eosinophil adhesion was calculated by measuring residual eosinophil
peroxidase activity of adherent cells. Fifty microliters of eosinophil
peroxidase substrate (1 mM H2O2, 1 mM o-phenylenediamine and
0.1% Triton X-100 in Tris buffer pH 8.0) were added to each well. After
30 min of incubation at room temperature, 25 ml of 4M H2SO4 were
added to each well to stop the reaction and absorbance was measured
at 490 nM with a microplate reader (Versamax, Molecular Devices,
Sunnyvale, CA, U.S.A.). Adherence was calculated by comparing
absorbance of unknowns to that of the standard curve.
2.6. Measurement of cytokine concentrations in lungs
After accurately weighing, 50 mg of airway tissues was homogenized
in 1.0 ml of buffer (10 mM potassium phosphate buffer, 0.1 mM EDTA,
pH 7.4) containing protease inhibitor cocktails. These homogenates were
centrifuged at 800×g for 10 min at 4 °C. The supernatant fraction was
then removed and stored at −80 °C. IL-4, IL-5, IL-10, IL-13, eotaxin,
TNF-α and IFN-γ levels in the lung tissue supernatant were determined
using a commercial immunoassay kit obtained from R&D Systems
(Minneapolis, USA). The minimum detectable levels of mouse IL-4, IL-5,
IL-13, eotaxin were 2.0, 7.0, 1.5 and 3.0 pg/ml, respectively.
2.7. Flow cytometric analysis
Bone marrow and peripheral blood cells, collected at 24 h and 48 h
after OVA-challenge, were stained with FITC-conjugated anti-CCR3,
Fig. 1. Effect of 1400Won the eosinophil content in the bonemarrow and BAL of ovalbumin
(OVA)-sensitized and challenged mice. Bone marrow (A) and BAL (B) eosinophils were
obtained from sensitized mice at 24 h (n=13), 48 h (n=18), 72 h (n=12) and 96 h
(n=12) after intranasal administration of OVA; non-challenged mice (NC, n=4) received
only saline intranasally. Open columns represent data of OVA-challenged control (non-
treated) and 1400W-treatedmice and gray columns represent those of non-challenged (NC)
animals. 1400W was administered intraperitoneally 2 h before and 4 and 12 h after the
intranasal challenge. Each column represents the mean ± S.E.M. #Pb0.05 compared to
respective group at 24 h.
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conjugated anti-CD11a. Flow cytometric analysis of the cells with a high
content of granules/CCR3+ were performed with a FACS-Aria (Becton-
Dickson) using the software FACS-DIVA (BD-Bioscience). The ﬂuores-
cence intensity of each cell was compared to that of isotype controls.
2.8. Statistical analysis
Data are expressed as the mean ± S.E.M of n experiments and
were analyzed by Kruskal–Wallis nonparametric analysis of variance
(ANOVA) followed by Dunn's multiple comparisons test, or the
Mann–Whitney test. Statistical signiﬁcance was established as
pb0.05.
3. Results
3.1. Effect of iNOS inhibition upon eosinophil counts in the bone marrow
and bronchoalveolar lavage of antigen-challenged mice
Initially, we investigated whether 1400W treatment interferes
with eosinophil migration from bone marrow to the lungs. The
eosinophil content in the bone marrow and bronchoalveolar lavage
(BAL) of groups of immunized mice was veriﬁed at 24 h, 48 h, 72 h
and 96 h after intranasal administration of OVA (challenged group) or
saline (non-challenged group). These analyses were carried out in
both the control (non-treated) and 1400W-treated groups.
Challenge of sensitized mice with OVA resulted in a signiﬁcant
increase in the number of bone marrow eosinophils in both control and
1400W-treated mice, compared to their respective non-challenged
groups (Fig. 1A). At 48 h, the eosinophil content was signiﬁcantly
reduced in the bone marrow of control mice, but remained at a similar
number to that observed at 24 h in 1400W-treated mice (Fig. 1A). As a
result, a signiﬁcant difference between these groups was observed at this
time. Treatment with 1400W did not alter the eosinophil number in
bone marrow at 24 h, 72 h and 9 h after antigen challenge (Fig. 1A).
The analyses of leukocyte population present in the BAL of the
control group showed that eosinophil inﬁltration had started by 24 h and
that a marked increase, beginning at 48 h, persisted until 96 h after
OVA-challenge in this group (Fig. 1B). 1400W treatment produced an
inhibition in the OVA-induced inﬂux of eosinophils into the BAL ﬂuid at
48 h after antigen challenge (Fig. 1B). This effect was not sustained even
with repeated administration of 1400W, since the eosinophil number in
the BAL of treated mice was similar to that seen in control mice at 96 h
(Fig. 1B). Eosinophils were virtually absent in the BAL of non-challenged
mice of both control and 1400W-treated groups.
3.2. The effect of the NOS inhibitor, 1400W, on integrin expression on
bone marrow and blood eosinophils
To verify whether the reduced inﬂux of eosinophils to the lung of
iNOS-inhibited mice was associated with adhesion molecule expression,
we investigated the effects of 1400W treatment on LFA-1 (CD11a/CD18),
Mac-1 (CD11b/CD18) and VLA-4 (CD49d/CD29) expression. The integrin
expressions on eosinophils obtained from the bone marrow and
peripheral blood at 24 h and 48 h after OVA-challenge, as well as the
frequency of positive cells, were evaluated by ﬂow cytometry.
Initially, the time course of adhesion molecule expression on cells
from the control group (non-treated mice) was determined. Cytometric
analysis of eosinophils from bone marrow and peripheral blood of
control mice showed that LFA-1 expression was 5 times higher on blood
eosinophils, as compared to bone marrow cells, and did not change at
any time studied (Fig. 2A). However, Mac-1 expression on bone marrow
eosinophils from the mice of the control group was signiﬁcantly
increased at 48 h, as compared to 24 h. In contrast, at the same time, a
signiﬁcant inhibition in Mac-1 expression was seen on blood eosinophils
(Fig. 2B). The expression of VLA-4 did not ﬂuctuate on bone marroweosinophils from control mice at any time examined. Nevertheless, a
signiﬁcant reduction in VLA-4 expression was observed in blood
eosinophils at 48 h after antigen challenge in control mice (Fig. 2B).
As seen in the control group, whilst the expression of LFA-1 was
higher on blood eosinophils, the expression of LFA-1 on bone marrow
and peripheral blood eosinophils of 1400W-treated mice did not
change at any time studied (Fig. 2A). Treatment of mice with 1400W
resulted in an augmented Mac-1 expression on bone marrow
eosinophils at 24 h, as compared to control mice (Fig. 2B). At this
time, the 1400W treatment had no effect upon VLA-4 expression on
bone marrow eosinophils (Fig. 2C). However, 1400W reduced
signiﬁcantly the expressions of Mac-1 and VLA-4 on peripheral
blood eosinophils at 24 h (Fig. 2B and C). In contrast, at 48 h,
treatment increased signiﬁcantly the expressions of Mac-1 and VLA-4
on blood eosinophils (Fig. 2B and C).
Flow cytometric analysis showed a discrete alteration in the
frequencies of CD11a+ and CD49d+ eosinophils in the bone marrow of
control mice, as compared with those of 1400W-treatedmice at all times
studied (Table 1). In contrast, treatment with the inhibitor led to a
signiﬁcant increase in the frequency of CD11b+ eosinophils in the bone
marrow, at 24 h (Table 1). In the peripheral blood of 1400W-treatedmice,
the frequency of CD49+ eosinophils dropped signiﬁcantly in relation to
the control group at 48 h after challenge with OVA (Table 1). Discrete
alterations in the frequencies of CD11a+, CD11b+ and CD49d+
eosinophils could be observed in the peripheral blood of mice treated
with 1400W, as compared with controls at other times (Table 1).
Fig. 2. Inﬂuence of 1400Won expressions of LFA-1 (CD11a),Mac-1 (CD11b) andVLA-4 (CD49d) on eosinophils of OVA-sensitized and challengedmice. Cellswere collected frombonemarrow
andperipheral bloodat24 hand48 hafterOVA-challengeofboth1400W-treatedanduntreated(control)mice, and thenstainedwithFITC-conjugatedanti-CCR3,PeCy7-conjugatedanti-CD11a,
APC-conjugated anti-CD11b and PE-conjugated anti-CD49d . Analyses of frequency of cells with high content of granules/CCR3+ (eosinophils) were performed by ﬂow cytometry (FACS-Aria)
using the software FACS-DIVA. Histograms represent the geometric means of ﬂuorescence intensity for CD11a (A), CD11b (B) and CD49d (C) expression on eosinophils. The values are
representative of 3 independent experiments. *Pb0.05, **Pb0.01, ***Pb0.001 and ****Pb0.0001 compared to respective control group.
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marrow and peripheral blood to VCAM-1 and ICAM-1
In order to determine whether treatment with 1400W inﬂuences the
function of Mac-1 (CD11b/CD18) and VLA-4 (CD49d/CD29) after OVA-
challenge, we investigated the adhesive proprieties of eosinophils from
bonemarrow and peripheral blood to ICAM-1- or VCAM-1-coated plates.
As shown in Fig. 3A, the acute treatment of allergic mice with 1400W
resulted in a signiﬁcant elevation of in vitro adhesion of bone marrow-derived eosinophils to ICAM-1 at 24 h and 48 h, as compared to control
cells. No differences were observed in the binding of peripheral blood
eosinophils to ICAM-1 at either time (Fig. 3C).
While adherence to VCAM-1 of bone marrow eosinophils obtained
from 1400W-treated mice at 24 h was similar to that of the control, a
signiﬁcant decrease in adhesion was observed with cells obtained at 48 h
(Fig. 3B). Adhesion to VCAM-1 of blood eosinophils from treated mice
was signiﬁcantly decreased at 24 h and at 48 h after OVA-challenge, as
compared to controls (Fig. 3D). The Mac-1 or VLA-4 antibody blocking
Table 1
Frequency of CD11a+, CD11b+ and CD49b+ cells in bone marrow and peripheral blood
of OVA-challenged mice following treatment with 1400W.
CD11a+ (%) CD11b+ (%) CD49d+ (%)
24 h 48 h 24 h 48 h 24 h 48 h
Bone marrow
Control 38±0.5 42±1,0 25±0.2 43±0.3 44±0.5 26±0.4
1400W 35±0.5 34±0.7 36±0.4* 54±1.5 43±0.8 27±0.5
Peripheral blood
Control 73±0.3 75±0.9 65±0,7 62±0.7 56±0.9 36±0.7
1400W 67±1.0 79±1.7 61±0.4 54±1.3 40±0.5 12±0.4***
Bone marrow and peripheral blood leukocytes were collected 24 h and 48 h after OVA-
challenge from mice treated or not (control) with 1400W. The cells were stained with
FITC-conjugated anti-CCR3, PeCy7-conjugated anti-CD11a, APC-conjugated anti-CD11b
and PE-conjugated anti-CD49d and analyzed byﬂowcytometry, as described in Fig. 4 . The
values are representative of 3 independent experiments. ⁎Pb0.05 and ***Pb0.001
compared to the control group.
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binding of eosinophils to ICAM-1 or VCAM-1, respectively, by at least
50%.3.4. Evaluation of cytokines in the lung tissue
The changes in cytokine levels were measured in lung tissue
homogenates from control or 1400W-treated mice at 24 h, 48 h, 72 h
and 96 h after antigen challenge. Initially, OVA-challenge induced
signiﬁcant increases in all cytokine levels of the control group at
different times, as compared to the non-challenged group (Fig. 4). In
the lung tissue of controls, the peaks of IL-4 and IL-13 were observedFig. 3. Effect of 1400Won the adhesion of bonemarrow and peripheral blood eosinophils to ICAM
OVA-sensitizedcontrol (non-treated) and1400W-treatedmice at24 hand48 hafter antigenic chal
Cells (1×106 cells/ml) were pre-incubated with MEM alone (open columns) or with the neutrali
columns) for 20 min at 4 °C before allowing cells to adhere to ICAM-1 (A and C) or VCAM-1 (B an
activity of adhered cells to that of a standard curve. Results are expressed as mean ± S.E.M of sixat 24 h and 48 h, respectively, and a decrease was observed in these
levels until 96 h after antigen challenge (Fig. 4A and C). The levels of
IL-5 in lungs increased signiﬁcantly in the ﬁrst 24–48 h, but returned
to basal levels at 72-96 h after challenge (Fig. 4A). Higher levels of
eotaxin in the lungs of control mice were observed between 48 h and
72 h and then decreased signiﬁcantly at 96 h after OVA-challenge
(Fig. 4D).
Treatment with 1400W signiﬁcantly reduced the levels of IL-4 in
lung tissue at 24 h and 48 h after challenge with OVA (Fig. 4A). On the
other hand, treatment was also able to reduce the levels of IL-5 at 48 h
(Fig. 4B), as well the levels of IL-13 and eotaxin at 48 h and 72 h
(Fig. 4C and D). No effect of 1400W treatment on any of the cytokines
studied was detected at 96 h after antigen challenge (Fig. 4).4. Discussion
Our data show that iNOS inhibition has a temporal effect upon
Mac-1 and VLA-4 expression on the sensitized mice bonemarrow and
peripheral blood eosinophils following antigen challenge, as well as
on eotaxin and Th2-isotype cytokine production.
In our previous study using the non-speciﬁc NOS inhibitor L-NAME
[13] and in this, using speciﬁc iNOS inhibition by 1400W treatment, we
have demonstrated that NO modulates the eosinophil inﬁltration into
the lungs and the efﬂux of bone marrow eosinophils to peripheral blood.
Therefore, we have investigated whether 1400W treatment could affect
integrin expression on the bone marrow and peripheral blood
eosinophils. Additionally, these cells' ability to adhere to VCAM-1- and
ICAM-1-covered plates was evaluated.
Analysis by ﬂow cytometry has shown that the Mac-1 expression
was lower in the control group (non-treatedmice) eosinophils in both-1 and VCAM-1. Eosinophils were obtained from bonemarrow (BM) and peripheral blood of
lenge; 1400Wwasadministered intraperitoneally at2 hbeforeand4and12 hafter challenge.
zing antibodies anti-Mac-1(α CD11a - 10 μg/ml) and anti-VLA-4 (α CD49d - 10 μg/ml; gray
d D)-coated plates (30 min, 37 °C, 5% CO2). Cell adhesion was calculated by comparing EPO
independent experiments with three replicates in each.
Fig. 4. Effect of 1400W on lung tissue cytokines of ovalbumin (OVA)-sensitized and challenged mice. Lungs were collected at 24 h (n=13), 48 h (n=18), 72 h (n=12) and 96 h
(n=12) after intranasal OVA-challenge, and homogenized in phosphate buffered saline (1.0 ml PBS/150 mg of lung tissue). The levels of IL-4, IL-5, IL13 and eotaxin were determined
in tissue extracts using speciﬁc ELISA tests. Non-challenged group (NC; n=4) received only saline intranasally. Results of non-challenged mice represent a pool of cytokine levels at
24 h, 48 h, 72 h and 96 h. Each column represents the mean ± S.E.M. +Pb0.05 compared to the NC group.
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for eosinophils in the bone marrow and at 48 h for blood eosinophils.
Nevertheless, a signiﬁcant reduction of VLA-4 expression was
observed in blood eosinophils at 48 h in control mice. These results
suggest that, in sensitized mice, eosinophil integrin expression
downregulation can reduce cell adherence to bone marrow and
peripheral blood compartments, facilitating cell egress from the bone
marrow to the circulation and from blood to lungs at distinct times
after antigenic challenge. This is in agreement with different studies
describing the eosinophil time course efﬂux from bone marrow and
their migration to the lung after antigen challenge in sensitized
animals [13,18,19]. Furthermore, our study shows, for the ﬁrst time,
that Mac-1 might play an important role in bone marrow eosinophil
mobilization at 24 h, whereas both Mac-1 and VLA-4 are involved in
eosinophil migration from the peripheral blood to lungs at 48 h after
OVA-challenge. Treatment of mice with 1400W resulted in a
signiﬁcant increase in the Mac-1 expression on bone marrow
eosinophils at 24 h after antigen challenge that has also been
associated with augmentation in the Mac-1+ eosinophil frequency,
as compared to control mice. This has also been accompanied by the
adhesion increase of eosinophils to ICAM-1. No effect was seen, at this
time, neither upon the VLA-4 expression nor the adherence to VCAM-
1 of bone marrow eosinophils. However, at 24 h, treatment with
1400W decreased the expressions of Mac-1 and VLA-4 on blood
eosinophils by about 40% and 76%, respectively; Mac-1 and VLA-4
expressions augmented at 48 h after treatment. Interestingly, while
VLA-4 expression was increased, the frequency of blood eosinophils
bearing this integrin was reduced by 66%, as compared to control. This
fact could explain the discrepancy observed between the results of in
vitro adhesion to VCAM-1 (68% of inhibition) and VLA-4 expression(64% increase) observed in ﬂow cytometry analysis. But, its real
signiﬁcance in the eosinophil migration of to the lung needs to be
studied. Taken together, these results suggest that the inhibition of
iNOS produces an augmented Mac-1 expression on bone marrow
eosinophils at 24 h, as well as an increase in the expression of Mac-1
and VLA-4 on peripheral blood eosinophils at 48 h. The eosinophil
adhesion molecules expression modulation of 1400W-treated mice
may be related to the reduced bone marrow and blood eosinophil
mobilization, resulting in an impaired inﬂux of these cells to the lungs.
We have previously observed temporal alterations in the adhesion
of bone marrow eosinophils to ﬁbronectin, following OVA-challenge,
in a model of chronically L-NAME-treated rats [13]. However the
current study, employing VCAM-1/ICAM-1-coated plates and ﬂow
cytometry analysis, has identiﬁed the Mac-1 integrin as the main
adhesion molecule responsible for this event in the bone marrow. In
addition, we may suggest that the expressions of VLA-4 and Mac-1 on
blood eosinophils were inﬂuenced by treatmentwith 1400W andmay
have a role in the inhibition of lung eosinophil inﬁltration. In both
compartments, 1400W may increase the adhesive interactions
between integrins and their ligands, by changing the afﬁnity binding
or the conformation of integrin molecules, thus delaying the cell
migration. In fact, it has been shown that treatment with L-NAME
induces an increase in the adhesion of human eosinophils to the
ﬁbronectin and serum that can be abolished by speciﬁc anti-CD49d-
and anti-CD11a monoclonal antibodies [20]. This study showed that
NO might decrease the expression of Mac-1, as well as the function of
VLA-4 (via alterations in afﬁnity or avidity), on the eosinophil surface.
Human PMN treated with L-NAME has also been shown present
signiﬁcant increases in their adhesion to ﬁbronectin and serum. These
effects were reversed by dihydrochalasin B and nocodazole
210 E.H. Pelaquini et al. / International Immunopharmacology 11 (2011) 204–211(microﬁlament and microtubule depolymerizing agents) suggesting
that endogenously produced NO may have a role in inhibiting the
adhesion of human neutrophils to extracellular matrix components
[21].
In the study of cytokine production, we have also veriﬁed that
antigen challenge induced an increase in eotaxin and Th2 cytokines
(IL-4, IL-5, and IL-13) levels, which is consistent with the induction of
an allergen-driven Th2 response [22–24]. It has been suggested that
the hyper production of Th2 cytokines, along with increases in the
mast cell number, in the lung tissue of BALB/c mice, may implicate a
role for these factors in early or mild asthma [25].
Cytokines have been reported to act as both modulators and
targets of modulation by NO. For instance, IL-10 and IL-4 have been
known to reduce NO production by murine macrophages through
inhibition of iNOS activity [26–28]. On the other hand, it has been
reported that IL-13 increases NO release in human bronchial epithelial
cells, in association with iNOS gene and protein expression [29]. Our
current study has shown that, in association with the reduced
eosinophil inﬁltrate, allergic mice treated with 1400W showed
decreased levels of IL-4, IL-5, IL-13 and eotaxin in the lung tissue at
different times after antigen challenge. At about 24 h to 48 h after
treatment with 1400W, there was a decrease in IL-4, while the levels
of IL-5 were reduced by this treatment only at 48 h. It was observed
that 1400W also induced decline in IL-13 and eotaxin levels between
48 h and 72 h. Our data suggest that NO production may be a crucial
factor in regulating the initial events of the allergic response
orchestrated by IL-4, such as the inﬂux of eosinophil, without
affecting the proﬁle of serum speciﬁc immunoglobulin, as it has
been seen by us and others [11,13,30,31].
In addition to their effect on IgE switching, IL-4 is involved in the
differentiation of Th0 cells to Th2 cells, which leads to increased
production of IL-5 and other cytokines that promote eosinophilia [32].
IL-4 is also a potent inducer of eotaxin secretion [33], which in turn
acts synergistically with IL-5 to induce eosinophil migration [34,35].
Our study suggests that the reduction in airway eosinophil number,
seen in 1400W-treated mice, could be a consequence of the reduction
in Th2-cell function in the lungs and, consequently, of the diminished
levels of Th2 cytokines.
In conclusion, our results suggest the involvement of iNOS in the
expression of adhesion molecules on eosinophils from both bone
marrow and blood that may inﬂuence the migration of cells to the
lungs of allergic mice. In our model, NO seems to produce a temporal
effect on the expression and function of Mac-1, suggesting this to be
the chief adhesion molecule involved in eosinophil efﬂux from the
bone marrow at 24 h, whilst Mac-1 and VLA-4 were involved in
eosinophil mobilization from peripheral blood to lungs at 48 h after
antigen challenge. Similarly, NO seems to modulate the production of
Th2-cytokines such as IL-4, IL-5, IL-13 and the CC chemokine eotaxin
in the lung tissues. All of these are involved in eosinophil migration to
the airways.
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